These two promising RNAi drug developers are trading at hefty premiums going into 2020.
News & Analysis: Dicerna Pharmaceuticals
What goes up must come down. But today's tumble means relatively little for investors with a long-term mindset.
A $9.7 billion deal and two failed takeover bids ushered in renewed enthusiasm for acquisitions in the pharmaceutical industry. What makes these stocks buyout candidates?
This early-stage biopharma is developing a promising gene-silencing pipeline that's beginning to turn heads.
The small-cap biopharma inked a deal with a major pharmaceutical company, its second in three weeks.
DRNA earnings call for the period ending September 30, 2019.
DRNA earnings call for the period ending June 30, 2019.
DRNA earnings call for the period ending March 31, 2019.
DRNA earnings call for the period ending December 31, 2018.
Investors ponder the biotech's secondary offering.